Daiichi Sankyo, a global pharmaceutical company, is seeking in vitro models to assess immune-mediated organ toxicity for drug safety, as well as advanced in vitro models to evaluate drug efficacy in breast and lung cancers.
Approaches of Interest:
<ul>
<li>Assessment of immune-mediated organ toxicity for drug safety
<ul>
<li>In vitro models to evaluate immune-mediated organ toxicities caused by pharmaceutical compounds, such as immuno-oncology drugs, in humans</li>
<li>The ability to detect the risk potential of drug-induced immune-mediated organ toxicity in humans using appropriate endpoint evaluations and to justify the validity of those evaluations using clinical drugs</li>
<li>Evaluation models incorporating technologies such as Microphysiological Systems (MPS) or co-culture systems with immune cells are of interest, although a simpler and precise approach would be preferred </li>
<li>Models for all organs are of interest, with particular emphasis on vital systems including lung or heart </li>
</ul>
</li>
<li>In vitro assay models for drug efficacy assessment
<ul>
<li>Repeatable and quantitatively measurable in vitro assay models/systems using iPSC-derived cells and patient-derived organoids to assess drug efficacy for breast and lung cancers</li>
<li>Model should be validated using multiple existing drugs, and drug-resistant models are also of interest</li>
<li>Assay models incorporating technologies such as MPS and imaging analysis techniques are also of interest</li>
</ul>
</li>
</ul>
Out of Scope:
<ul>
<li>Single-use test systems for drug efficacy assessments</li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Basic research through to clinical development with promising and unique technologies is within scope</li>
</ul>
Submission Information
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Our client is also open to novel research proposals which can be outlined using this <a href="">submission form</a>. In submitting to this campaign, you confirm that your submission contains only non-confidential information.
Opportunity for Collaboration
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, MTA, and research collaborations.

Daiichi Sankyo is seeking in vitro models to assess immune-mediated organ toxicity for drug safety, as well as advanced in vitro models to evaluate drug efficacy in breast and lung cancers.

In Vitro Assay Models for Drug Safety and Efficacy Assessment

The Impulse by Chiesi, the Open Innovation team within the global research-oriented biopharmaceutical group, is launching a call for opportunities focused on novel drug delivery systems to enhance drug targeting and patient outcomes. Through Inpart Connect, the team seeks innovative solutions in three defined areas of interest.
Oral delivery of biologics - oral administration of peptides, proteins or more complex biotherapeutics to support home-based care, improve adherence and simplify treatment. Approaches should address enzymatic degradation and poor intestinal absorption, which restrict the feasibility of oral delivery. Novel formulations, devices, or enabling technologies are within scope. 
Non-Invasive delivery to bypass the blood-brain-barrier - enhance therapeutic outcomes and patient experience, by enabling non-invasive drug delivery routes (e.g. intranasal) that bypass the blood-brain barrier. Solutions that improve targeting efficiency, bioavailability, and ease of use, whether through novel formulations, devices, or biological mechanisms.
Personalized and customizable delivery systems for ultra-precise dosing - delivery systems to tailor dosing for individual needs, which is critical in areas like paediatrics, geriatrics and rare diseases. Any solution that allows flexible, on-demand production of personalized dosage forms, with priority given to modular, scalable platforms. Strategies to enable doses to be adapted based on patient-specific characteristics such as age, weight, disease progression, or monitored clinical indicators (e.g., biomarkers, organ function), enabling dynamic and responsive treatment strategies. 
<ul>
<li>Oral, lung, nasal, parenteral intranasal, and other non-invasive approaches are in scope.</li>
<li>Developmental Stages of Interest: Solutions with TRL 3-6 are of high interest. Submissions should have a minimum of in vitro validation, with a preference for in vivo data or first in-human studies. </li>
<li>Out of Scope: Diagnostic approaches or methods, analytical technologies, oral delivery of small molecules. Submissions from individual physicians or others working in hospital/private practice. </li>
</ul>
Submission Information: Submissions should include a one-page summary (200–300-words) along with any supplementary information such as relevant publications or patents. Applicants are strongly encouraged to include a slide-deck (or similar presentation) outlining their solution and plans to bring it to market for patient benefit. Chiesi welcomes submissions from all applicants, including early-stage researchers, using this <a href="">submission form</a> to describe their research and proposed next steps.
The Impulse by Chiesi is open to a range of collaboration models, including support for small proof-of-concept or pilot studies to validate solutions that align with its needs. Details regarding intellectual property and licensing will be discussed on a case‑by‑case basis. By submitting to this campaign, you confirm that your submission contains only non-confidential information.

Chiesi is seeking novel drug delivery solutions to achieve oral delivery of biologics, and non-invasive delivery of drugs across the blood-brain barrier.

Seeking Non-invasive and/or Personalized Delivery Systems for Complex Therapies

Certis Belchim, an expert in crop protection, is seeking novel technologies to optimize the production and reduce the application cost of its herbicide, metobromuron. Specifically, the team is interested in approaches that reduce the cost to produce the metobromuron compound or formulation improvements that reduce the dose rate of the herbicide. All approaches should be able to be scaled up to industrial quantities. In the evaluation of the proposals a feasibility study will be made. Ballpark prices of final proposal or cost reduction benchmarks with the proposed technologies are highly appreciated.
Optimization of the production process:
<ul>
<li>New chemical synthesis methods that achieve minimum gram level quantities, preferentially kg or ton level </li>
<li>Open for new production technologies, e.g. continuous flow reactors, enzymatic production, etc. </li>
<li>Improvements that make the production process more environmentally friendly are also of interest </li>
</ul>
Optimization of the formulation:
<ul>
<li>Open to a range of formulation methods, e.g. capsule suspensions, oil-based formulations, etc. </li>
<li>Adjuvants and enhancers that reduce the dose rate of the herbicide are of interest </li>
<li>Mixtures of metobromuron with other herbicides that would achieve the same effect with a reduced cost </li>
</ul>
Out of Scope:
<ul>
<li>Chemical syntheses that only achieve microgram quantities </li>
<li>Novel herbicides and methods that cannot be applied to metobromuron </li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Opportunities should have at least lab-based proof of concept with a relevant example compound </li>
</ul>
Submission Information and Opportunity for Collaboration
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications and benchmarks on cost improvements are highly appreciated. This campaign is open to submissions from SMEs and start-up companies. Submitters ideally have experience on industrial scale. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets and research collaborations. Successful submissions could lead to a joint development program with Certis Belchim to develop the approach on an industrial scale.

Certis Belchim is seeking approaches to optimize the production process and formulation of the herbicide metobromuron.

Seeking Approaches to Reduce the Application Cost of an Agrochemical Active Ingredient

Daiichi Sankyo, a global pharmaceutical company, is seeking research on in vivo animal models and in vitro cell/tumor tissue models exhibiting resistance to immune checkpoint inhibitors (ICIs).
<h3>Approaches of Interest:</h3>
<ul>
<li>The mechanism of resistance (MoR) is clearly defined and is tumor-intrinsic </li>
<li>The PD-1 and PD-L1 immune checkpoint pathways are of highest interest</li>
<li>Research focused on solid tumors (lung, breast and pancreatic tumors are of primary interest)</li>
<li>The MoR to ICI reflects clinical observations </li>
<li>The MoR to ICI is associated with specific patient selection biomarker </li>
</ul>
<h3>Out of Scope:</h3>
<ul>
<li>Submissions relating to blood cancers </li>
<li>Opportunities that lack a clear MoR or have tumor-extrinsic MoR </li>
</ul>
<h3>Developmental Stages of Interest:</h3>
<ul>
<li>Opportunities from basic research to registration are in scope providing there is a clear MoR</li>
</ul>
<h3>Submission Information</h3>
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Our client is also open to novel research proposals which can be outlined using this <a href="">submission form</a>. In submitting to this campaign, you confirm that your submission contains only non-confidential information.
<h3>Opportunity for Collaboration</h3>
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Daiichi Sankyo is seeking research on in vivo animal models and in vitro cell/tumor tissue models exhibiting resistance to immune checkpoint inhibitors. 

Seeking In Vivo and In Vitro Models Exhibiting Resistance to Immune Checkpoint Inhibitors

Daiichi Sankyo, a global pharmaceutical company, is seeking novel oligonucleotide-based approaches to efficiently and specifically increase or decrease target RNAs both in vitro and in vivo for developing new treatments. Additionally, cutting-edge RNA editing techniques are also of interest.
Approaches of Interest:
<ul>
<li>Novel oligonucleotide-based technology that can control RNA expression levels or change RNA sequences e.g., dual-targeting antisense oligonucleotides (ASOs) and advanced RNA editing technologies</li>
<li>Novel technologies for efficient transport from extracellular space into cytosol, nucleus or mitochondria e.g., chemically modified oligonucleotides to enhance transport from the cytosol into the nucleus</li>
<li>Novel target-identification methods for oligonucleotide-based approaches such as ASO and RNA editing</li>
<li>Research findings on novel biological regulatory pathways or molecules that control RNA transcription, splicing, translation, or transport, with potential for future development as described in the previous three bullet points
<ul>
<li>Opportunities should demonstrate how the newly identified RNA targets could contribute to treating specific diseases</li>
</ul>
</li>
</ul>
Out of Scope:
<ul>
<li>Packaging technologies/delivery systems (e.g. viral vectors, nanoparticles)</li>
<li>For submissions relating to ASOs, RNA editing techniques, and conventional technologies that modulate RNA by endogenous Ago2, RNase H or ADAR are out of scope</li>
<li>Submissions based on hypothetical ideas or lacking sufficient proof-of-concept</li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Submissions must include, at minimum, in vitro data; in vivo data is preferred </li>
</ul>
Submission Information
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Our client is also open to novel research proposals which can be outlined using this <a href="">submission form</a>. In submitting to this campaign, you confirm that your submission contains only non-confidential information.
Opportunity for Collaboration
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Daiichi Sankyo is seeking novel oligonucleotide-based approaches to increase or decrease target RNAs both in vitro and in vivo for developing new treatments. Cutting-edge RNA editing techniques are also of interest.

Innovative Oligonucleotide Strategies for Targeted RNA Expression Modulation

Daiichi Sankyo, a global pharmaceutical company, is seeking evaluation systems and biomarkers suitable for non-clinical studies in the fields of neurodegenerative diseases (ALS, AD) with high translational potential for clinical application. In the immunology domain, their interest is specifically limited to systems for accurately predicting human immunogenicity caused by intracellularly expressed proteins from gene therapy. 
Approaches of Interest:
<ul>
<li>Evaluation systems and biomarkers in neurodegenerative diseases
<ul>
<li>In vitro and in vivo evaluation models with human translatability that replicate multiple aspects, such as loss of function and gain of toxic function, of TDP-43 proteinopathy in ALS alone</li>
<li>Potential biomarkers for ALS that reflect either gain-of-function (GoF) or loss-of-function (LoF) mechanisms of TDP-43, or both, identified through analyses of patient-derived samples (e.g., STMN2, UNC13A mis-splicing)</li>
<li>Potential biomarkers for AD that predict disease progression rate after onset, identified through analyses of patient-derived samples</li>
</ul>
</li>
<li>Systems for accurately predicting human immunogenicity caused by intracellularly expressed proteins from gene therapy
<ul>
<li>Excluding secreted proteins circulating in blood</li>
<li>In silico models are out of scope</li>
</ul>
</li>
</ul>
Developmental Stages of Interest:
<ul>
<li>All stages of research are of interest for evaluations systems and biomarkers providing there is proof-of-concept</li>
</ul>
Submission Information
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Our client is also open to novel research proposals which can be outlined using this <a href="">submission form</a>. In submitting to this campaign, you confirm that your submission contains only non-confidential information.
Opportunity for Collaboration
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include project/PhD funding and research collaborations.

Daiichi Sankyo is seeking evaluation systems and biomarkers suitable for non-clinical studies in the fields of neurodegenerative diseases. In the immunology domain, they are interested in systems for accurately predicting human immunogenicity .

Development and Identification of Novel Evaluation Systems and Biomarkers for Gene Therapy in Neurodegenerative Diseases and Immunology

A mid-cap publicly traded US Pharma company specializing in rare diseases with a highly efficient global commercial team is seeking assets for a wide range of rare disease indications that have reached clinical development. Our client’s pipeline consists of 3 products approved in several indications and 2 products in Phase 1-3. They are interested in expanding their portfolio with clinical-stage and commercial assets. 
<h3>Approaches of Interest: </h3>
<ul>
<li>Open to a wide range of therapeutic areas. A non-exhaustive list with some examples of diseases of interest can be found <a href="">here</a></li>
<li>Indications should have a patient population of 300 – 200,000 in the US</li>
<li>Open to a wide range of modalities, including small molecules, recombinant proteins, antibodies, and antisense oligonucleotides. Non-gene-therapy nucleic acid-based therapeutics are of particular interest </li>
<li>Repurposed drugs will be considered only if they have been reformulated into a new product for the rare indication </li>
</ul>
<h3>Out of Scope: </h3>
<ul>
<li>Cell therapy, gene therapy, and medical devices </li>
<li>Assets for oncology indications and psychiatric disorders </li>
<li>Assets that are under clinical development or marketed for non-rare indications </li>
<li>Generics, biosimilars, and natural products that are not IP-protected </li>
<li>Diagnostics and drug discovery platforms </li>
</ul>
<h3>Developmental Stages of Interest: </h3>
<ul>
<li>Opportunities from Phase 1 onwards (including commercial) are in scope </li>
<li>Opportunities that are Phase 2 onward are of highest interest </li>
</ul>
<h3>Submission Information </h3>
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. slide decks, relevant publications. Submissions that contain information on the therapeutic area, mechanism of action, modality, route of administration, patient population, and development stage will be prioritized. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 
<h3>Opportunity for Collaboration </h3>
Our client is open to a range of collaboration opportunities, with the main focus on licensing of assets.

A mid-cap publicly traded US Pharma company specializing in rare diseases with a highly efficient global commercial team is seeking assets for a wide range of rare disease indications that have reached clinical development.

Clinical and Commercial Stage Assets for Rare Indications

Asahi Kasei Pharma, a global pharmaceutical company, is seeking therapeutic strategies aimed at enhancing drug delivery to the kidney. Specifically, conjugate linker technologies capable of releasing small molecules—those with a molecular weight under 1000 and terminating in a carboxylic acid group.
Approaches of Interest:
<ul>
<li>Linker technologies that allow for carboxylic payload release in drug delivery systems </li>
<li>Conjugated compounds should be designed to remain stable during circulation and selectively cleave upon reaching the kidney. Compounds targeting alternative organs will be considered </li>
<li>Experimental evidence of carboxylic acid release is required, with particular interest in enzyme- or pH-dependent mechanisms</li>
<li>All modalities, including sequential methods, are acceptable if the technology can cleave the terminal carboxylic acid </li>
</ul>
Out of Scope:
<ul>
<li>Submissions based on theories </li>
<li>Submissions related to alcohol or amine release </li>
</ul>
Development Stages of Interest
Submissions will ideally have in vitro or in vivo evidence and those with experimental evidence of carboxylic acid release are of highest interest. 
Submission Information
Asahi Kasei Pharma invites applications from both academic and biotech organizations, and encourage submissions with experimental evidence of carboxylic acid release. Submissions based on existing technologies or methods are equally encouraged. Applicants should complete the <a href="">submission form </a>which should contain a brief, non‑confidential overview of your proposal, demonstrating how the requirements are satisfied by your approach. To submit, please visit our <a href="">website</a>, register, and submit your application form under the appropriate Connect campaign. 
Opportunity for Collaboration
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Asahi Kasei Pharma is seeking conjugate linker technologies capable of releasing small molecules—those with a molecular weight under 1000 and terminating in a carboxylic acid group.

Engineering Conjugated Linkers for Site-specific Drug Release in the Kidney 

Servier, a leading international pharmaceutical company, is seeking novel therapeutic proposals that target neuroinflammation and/or neuroimmunity in central nervous system and/or peripheral nervous system diseases. The team is particularly interested in approaches that have an already identified target, demonstrate the ability to counteract these pathological conditions, and offer a well-supported and differentiating pharmacological strategy for treatment. 
Approaches of Interest:
<ul>
<li>Diseases of interest are ALS (sporadic form and neuroinflammation associated with genetic form), autoimmune myasthenia gravis, chronic inflammatory demyelinating polyneuropathies, autoimmune nodopathies, autoimmune epilepsy, and autoimmune encephalitis </li>
<li>Other neuroinflammatory/ neuroimmune diseases will be considered but as a lower priority and only if they have a clear identified target. In all cases, the eligible patient population should be over 500 individuals </li>
<li>Modalities of interest include small molecules, antibodies, and antisense oligonucleotides</li>
<li>All targets and mechanisms of action related to neuroinflammation and/or neuroimmunity are in scope </li>
<li>Drug repurposing is of interest, provided there is clearly demonstrated involvement and proof of concept for one of the diseases of interest </li>
</ul>
Out of Scope:
<ul>
<li>Cell therapy, gene therapy, and medical devices </li>
<li>Broad or not-targeted anti-inflammatory approaches </li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Opportunities up to late preclinical stage are of interest, provided there is clear proof of concept, at least in vitro</li>
<li>Opportunities with in vivo proof of concept will be given priority </li>
</ul>
Submission Information
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications or supporting materials/ experimental data. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 
Opportunity for Collaboration
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets and research collaborations.

Servier is seeking therapeutic approaches that target neuroinflammation and/or neuroimmunity in a range of CNS and PNS diseases, including ALS, autoimmune myasthenia gravis, and autoimmune epilepsy.

Seeking Novel Druggable Targets in Neuroinflammation and Neuroimmunity 

A multinational pharmaceutical company is seeking new antibiotic compounds and adjuvants with antibacterial or antifungal activity or repositioned or repurposed molecules as novel therapeutics targeting multidrug-resistant bacterial pathogens. The focus is on agents that demonstrated antibacterial effects incidentally during development for unrelated indications. 
<h3>Approaches of Interest:</h3>
<ul>
<li>Repurposing non-antibiotic drugs </li>
<li>There is significant interest in clinical indications associated with ESKAPE pathogens as well as those caused by emerging pathogens such as Candida glabrata, Candida auris, and Aspergillus fumigatus</li>
<li>Combination therapies that overcome adverse effects of traditional antibiotics are preferred </li>
<li>Drugs that have advantages over traditional antibiotics specifically in resistance avoidance and safety profile</li>
</ul>
<h3>Developmental Stages of Interest:</h3>
<ul>
<li>Opportunities from preclinical research to registration are in scope 
<ul>
<li>For preclinical research, small molecules will be prioritised. Peptides are of limited interest, while biologics and non-molecular approaches are out of scope </li>
<li>For research in clinical trials and beyond, all modalities are in scope </li>
</ul>
</li>
</ul>
<h3>Submission Information</h3>
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 
<h3>Opportunity for Collaboration</h3>
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

A multinational pharmaceutical company is seeking new antibiotic compounds and adjuvants with antibacterial activity or repositioned or repurposed molecules as novel therapeutics targeting multidrug-resistant bacterial pathogens. 

New Approaches to Target Bacterial Infections 

A multinational consumer goods company is seeking novel condom materials and enhancements to existing polymers, with a focus on improving key performance attributes such as tensile strength, puncture resistance, low modulus (softer material) and heat transfer. Specifically, the team is interested in engaging with experts in material science, polymer chemistry, and elastomers to help co-develop next generation condom materials.
<h3>Approaches of Interest:</h3>
<ul>
<li>Our client is interested in researchers with expertise in rubber applications, including condoms, gloves, and tyres</li>
<li>Teams with experience working with polymers such as natural rubber latex, polyisoprene, polyurethane, and nitrile are of particular interest—especially those capable of enhancing key performance parameters such as tensile strength, thinness, heat transfer, modulus, and surface modifications of materials such as hydrophilic coatings</li>
<li>The client is also interested in innovative polymer solutions or manufacturing technologies that surpass current industry standards and address unmet consumer needs in condom design, including safety, comfort, and sensation</li>
</ul>
<h3>Developmental Stages of Interest:</h3>
Novel developments/proof of concepts which show promise as future solutions are of interest, although there is a preference for opportunities closer to market.
<h3>Submission Information</h3>
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. This campaign is open to submissions from SMEs and start-up companies. In submitting to this campaign, you confirm that your submission contains only non-confidential information.
<h3>Opportunity for Collaboration</h3>
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

A multinational consumer goods company is seeking novel condom materials and enhancements to existing polymers, and is interested in engaging with experts in material science, polymer chemistry, and elastomers.

Engage with world leading R&D teams

Active campaigns

ico